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Abstract
Objective: No standard second‐line treatment exists for acute graft‐versus‐host dis‐
ease steroid‐refractory (SR‐aGvHD), and long‐term outcomes remain poor. 
Mesenchymal stromal cells (MSCs) have been evaluated as treatment, but no disease 
model (DM) exists that integrates and extrapolates currently available evidence. The 
aim of this study was to develop such a DM to describe the natural history of SR‐
aGvHD and to predict long‐term outcomes.
Method: The DM was developed in collaboration with experts in haematology‐on‐
cology. Subsequently, a model simulation was run. Input parameters for transition 
and survival estimates were informed by published data of clinical trials on MSC 
treatment for SR‐aGvHD. Parametric distributions were used to estimate long‐term 
survival rates after MSCs.
Results: The newly developed DM is a cohort model that consists of eight health 
states. For the model simulation, we obtained data on 327 patients from 14 pub‐
lished phase II trials. Due to limited evidence, DM structure was simplified and sev‐
eral assumptions had to be made. Median overall survival was 3.2 years for complete 
response and 0.5 years for no complete response.
Conclusion: The DM provides a comprehensive overview on the second‐line treat‐
ment pathway for aGvHD and enables long‐term predictions that can be used to 
perform a cost‐effectiveness analysis comparing any treatment for SR‐aGvHD.
K E Y W O R D S
aGvHD, decision model, MSC, paediatric haematology, socioeconomics and ethics, stem cell 
biology, supportive care, transplantation
1  | INTRODUC TION
Despite decades of research, acute graft‐versus‐host dis‐
ease (aGvHD) is still one of the leading causes of death after 
haematopoietic allogeneic stem cell transplantation (HSCT) for both 
paediatric and adult patients.1,2 Immunosuppressive therapy with 
systemic corticosteroids is the first‐line treatment option. However, 
latest available studies estimate that about 50%‐70% of the patients 
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do not respond to this therapy.3‒5 Currently, there is no standard 
second‐line treatment available and outcomes in terms of morbidity 
and mortality remain poor.5‒9
Since 2004, mesenchymal stromal cells (MSCs) are increasingly 
studied in phase II clinical trials as a therapeutic option, demonstrat‐
ing positive treatment effects for steroid‐refractory (SR)‐aGvHD.10,11 
However, most of these trials are single‐arm studies or case studies 
or include a limited amount of patients (<50 participants), making 
reliable and meaningful conclusions challenging. Ideally, the effec‐
tiveness of MSC should be tested through phase III randomised 
controlled trials (RCTs), but these trials are difficult to perform due 
to regulatory and patient population‐related issues.11‒13 In 2010, 
results of one RCT (Prochymal; Osiris Therapeutics, Inc. Columbia, 
Maryland, United States) were released in the form of an unreviewed 
abstract.14 Further, a multicentre RCT is currently being conducted 
by the European Union Horizon 2020–funded research consortium 
RETHRIM (REgeneration THRough IMmunomodulation)15 (ie, the 
HOVON 113 MSC trial16). The latter study aims to determine the ef‐
ficacy and cost‐effectiveness of MSC as part of a second‐line treat‐
ment for aGvHD.
In the absence of reliable and conclusive RCT data, several op‐
tions exist to aggregate and synthesise currently available evidence 
of MSCs as a treatment option for SR‐aGvHD. These include meta‐
analyses, observational databases, the aggregation of expert opinion 
or decision analytic modelling.17 Thus far, four reviews that include 
currently available trials testing MSC as treatment for SR‐aGvHD 
have been published,11‒13,18 of which two are meta‐analyses.11,18 
However, none of the reviews combine available patient‐level data 
(PLD) of the phase II trials to predict and model long‐term outcomes 
of MSC treatment.
The aim of this study was to develop a disease model (DM) to de‐
scribe the natural history of SR‐aGvHD progression and its treatment 
pathways. The DM can be used to predict long‐term outcomes and 
cost‐effectiveness of current (eg, MSC treatment) and future treat‐
ment options for SR‐aGvHD. To test the practicability of the model, 
we aimed to gather and implement PLD of a second‐line treatment 
option. Ultimately, our model may facilitate clinical decision‐making 
under conditions of uncertainty.19‒21 When costs are added, this 
model can be a valuable tool for reimbursement decision‐makers. 22
2  | MATERIAL S AND METHODS
2.1 | Part 1: designing and structuring the model
2.1.1 | Model characteristics
The aim of the DM was 2‐fold. First, it needed to represent the natu‐
ral history of SR‐aGvHD and its treatment pathways in a simplified 
manner. Therefore, the DM focusses on the SR‐aGvHD only until pa‐
tients either progress, relapse, develop chronic GvHD or die. Second, 
it needed to be easily adaptable to a cost‐effectiveness model at a 
later stage. Therefore, the DM was built based on clinical expertise, 
previously published literature3,5,10,23,24 and the RETHRIM proto‐
col15. According to the ISPOR recommendations for good modelling 
practice,25 we consulted clinical experts to ascertain that the model 
represents the disease process and addresses the decision problem 
of determining which one second‐line treatment option is (cost‐)ef‐
fective when compared to another therapy option. We employed a 
convenience sample to include the clinical experts from the RETHRIM 
consortium. To be part of RETHRIM, consortium members needed 
to prove extensive research and treatment experience in the field of 
HSCT and work at a HSCT specialised treatment centre. All experts 
involved in this research thus have various professional backgrounds 
(eg, internal medicine, haematology, oncology or transfusion medi‐
cine) and originate from five EU member states (Germany, Italy, The 
Netherlands, Spain and Sweden). A European perspective on the dis‐
ease and treatment pathway(s) of SR‐aGvHD was hence ensured.
2.1.2 | Involvement of experts
Experts were consulted via email, during several telephone confer‐
ences and consortium meetings. This process was iterative until a 
final model version was regarded to fully represent the natural dis‐
ease and treatment pathway. In addition to the several consultations, 
the experts were asked to give written feedback on an earlier model 
version by means of a semistructured questionnaire. Choosing the 
appropriate model type (eg, decision tree, Markov process) was also 
based on the ISPOR recommendations for good modelling practice.25
2.2 | Part 2: model simulation
2.2.1 | Model input parameters
As MSCs are widely studied in numerous phase II clinical trials and 
case studies since 2004,10,13 we selected this treatment option 
to perform a model simulation. For the model input parameters, 
we identified relevant studies testing MSCs for the treatment of 
SR‐aGvHD from the recent reviews of Chen et al18, Munneke et 
al12 and Hashmi et al11 Additional PLD were obtained for stud‐
ies whose principal investigator was a member of the RETHRIM 
consortium.
Data were extracted using a prespecified extraction form aiming 
at capturing all available data that describe the disease and treat‐
ment pathway (see Appendix S1). The clinical effectiveness of MSC 
treatment was obtained from PLD of the reported first response 
evaluation or reconstructed from the published Kaplan‐Meier 
curves. Studies not reporting these data were excluded.
To extrapolate the survival data beyond the observed time hori‐
zon, we followed the 2013 updated NICE Decision Support Unit 
recommendations.26 Accordingly, considered parametric survival 
models for the DM included exponential, Weibull, Gompertz, log‐
logistic, lognormal and generalised gamma distributions. Parametric 
models were evaluated through visual inspection, Akaike’s informa‐
tion criterion (AIC) and Bayesian information criterion (BIC) tests as 
well as clinical validity according to the expert group.
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2.2.2 | Simulation
We ran a base‐case simulation with a hypothetical patient cohort 
comprising 100 patients with aGvHD grades II‐IV. Survival was mod‐
elled on a lifetime horizon, whereas it was assumed that patients do 
not exceed the age of 99 years.27 Health outcomes of the simulation 
were expressed in life‐years (LYs). As future health effects are valued 
lower than immediate effects,22 we adjusted future health outcomes 
(LYs) to “present values” according to the Dutch guideline for eco‐
nomic evaluations in health care.28,29
All statistical analyses were conducted in RStudio (version 
1.0.143, R version 3.4.1). Comprehensive R Archive Network (CRAN) 
packages used included survival, flexsurv, survminer and plyr.
3  | RESULTS
3.1 | Part 1: designing and structuring the model
3.1.1 | Model characteristics
We opted for a cohort‐based Markov model, which represents the 
most relevant responses and outcomes to second‐line treatment for 
aGvHD in corresponding health states. A Markov model consists of 
mutually exclusive health states that are associated with different 
outcomes and costs and provides an efficient structure to simulate 
a group of patients over time. Patients can change from one health 
state to another (ie, transit) at specified time interval (ie, cycles). 
Outcomes and costs are calculated for the entire time horizon of the 
model, taking into account the distribution of patients amongst the 
states at each cycle.30,31 Outcomes may entail clinical effectiveness 
outcomes (eg, response to treatment) as well as health‐related qual‐
ity of life (HRQoL) measures.
The DM comprises eight health states: (a) treatment for SR‐
aGvHD II‐IV, (b) response to treatment (complete or partial re‐
sponse), (c) sustained response, (d) treatment failure (stable or 
progressive disease), (e) relapse/persistent aGvHD, (f) third‐line 
aGvHD therapy, (g) relapse or adverse events of haematologic dis‐
ease requiring reinitiation or intensification of immunosuppression 
and (h) death (see Figure 1 for the model diagram). These states 
were primarily based on the HOVON113 MSC treatment protocol 
and expert opinion (see section “Involvement of experts”). Four re‐
sponse categories are defined: complete response (CR) is defined as 
the absence of all sign and symptoms of aGvHD; partial response 
(PR) is the improvement of aGvHD by at least one grade; stable 
disease (SD) is no change in aGvHD; and progressive disease (PD) 
is the worsening of aGvHD by at least one grade. The cycle dura‐
tion was set at 28 days according to the recommendation by Martin 
and colleagues on the standardised time period to evaluate aGvHD 
response.32 In addition, we applied a half‐cycle correction for the 
calculation of the model outcomes.
The model starts with treatment for SR‐aGvHD (a) at time 0 
(T0). Within 28 days after treatment (T28), patients either respond 
[ie, transit to the response to treatment health state (b)] or have a 
treatment failure (d) or die (h). Responders (b) can have a sustained 
F I G U R E  1   Design of the decision model for MSC treatment in aGvHD
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response (c), relapse or have a persistent aGvHD grade that requires 
the reinitiation or intensification of immunosuppression (e), or enter 
third‐line therapy (f).
Patients with a treatment failure to the initial MSC treatment (d) 
will directly receive third‐line treatment (f). Adverse events (AEs) of 
treatment are not defined as a separate health state, but are pos‐
sible within health states (b), and (d)‐(f). At any time and from any 
health state, patients can transit to relapse or experience of an ad‐
verse event of the underlining haematological disease (g), or death 
(h). Death is an absorbing health state, meaning that once entered, 
patients remain in this health state.
In the model, all health states are defined as mutually exclusive 
although in clinical practice patients may sometimes fit the criteria 
of multiple health states. In these cases, patients are assigned to the 
health state with the largest impact on outcomes and costs. For exam‐
ple, patients with treatment failure [health state (d)] may experience a 
relapse of the disease [health state (g)]. These patients are assigned to 
the relapse health state (g) although they also fit the criteria for treat‐
ment failure. The increasing numbering of the model states indicates the 
expected increasing impact on both outcomes and costs, according to 
expert opinion.
3.1.2 | Involvement of experts
The team of clinical experts consisted of eleven members from 
five different countries (Germany, Italy, the Netherlands, Spain and 
Sweden). A preliminary model based on the HOVON113 MSC treat‐
ment protocol was presented to all consortium members at the 
third RETHRIM consortium meeting. Because the structure of the 
model was deemed incomplete, alternative treatment pathways 
and additional health states were discussed in detail. This led to a 
refinement of the existing model states and to the addition of the 
following health states: relapse or adverse events of haematologi‐
cal disease, and adverse events. The new version of the model was 
then presented and discussed at the fourth RETHRIM consortium 
meeting. To allow for written feedback, experts were asked to fill 
out a semistructured questionnaire at the fifth consortium meeting. 
Subsequently, the model was amended and a final version was ap‐
proved by all experts.
3.2 | Part 2: Model simulation
3.2.1 | Model input parameters
We detected 18 studies that reported on phase II trials and collec‐
tion of case studies4,33‒49, of which 9 reported PLD33‒38,40,43,49 (see 
Appendix S2). Unpublished4,42 and additional data46 were requested 
and received for three studies. Two studies could be integrated by 
reconstructing the published Kaplan‐Meier curves.44,48 Three stud‐
ies were excluded because they did not publish survival data,47,50 
or the proportion of patients in the response categories.41 Patients 
reported in the study by Ringdén et al45 were not included as they 
had been already included in the data presented by Le Blanc and 
colleagues.4 From Lucchini et al49, only four patients with aGvHD 
stages II‐IV were included.
In total, we extracted data from 327 patients from 14 studies to 
estimate the proportion of individuals in the different health states 
and the proportion of patients changing between these states (ie, 
transition probabilities).31 Age and sex were only reported for 177 
and 152 patients, respectively, which made the originally planned 
subgroup analysis for age and sex impossible. All patients had aGvHD 
grades II–IV prior to MSC treatment; for 204 cases, the exact grade 
was known (18.6% aGvHD II, 45.6% aGvHD III and 35.8% aGvHD 
IV). Response categories in the underlying studies were defined het‐
erogeneously. Whereas one study did not provide any definition for 
the response categories employed,37 only complete response (CR 
=the complete resolution of all aGvHD symptoms) was unanimously 
defined in all other studies. Therefore, all response categories other 
than CR were grouped as “no complete response” (nCR).
Due to the lack of sufficiently detailed observational data, we 
were forced to use a simplified version of our model simulation. In 
this version, we could only model the first response to treatment (at 
day +28) and long‐term survival of patients after the first response 
evaluation to MSCs. The health states sustained response,4 relapse 
or persistent aGvHD,5 third‐line therapy, chronic GvHD,7 relapse or 
adverse events of haematological disease,8 and adverse events in 
general could not be modelled.
3.2.2 | Transition probabilities for the first two 
model cycles
Reported mean and median time of first evaluation was 26.6 and 
28 days, respectively (range = 2‐58). To integrate all available obser‐
vations into the model, we assumed that all responses were evalu‐
ated within the first 28 days after MSC treatment. Based on this, we 
calculated a transition matrix showing the probability of response to 
MSC after day 28 (see Table 1).
Table 1 shows that 43.4% patients with aGvHD II‐IV had a CR at 
first response evaluation whereas 43.7% had nCR, and 12.8% died 
within the first 28 days.
3.2.3 | Long‐term survival estimation
To extrapolate survival estimates beyond study observations, sur‐
vival data, available for 235 patients (115 CR, 120 nCR), were used. 
For the excluded cases, the last time of follow‐up or time to death 
was not reported. Patients who died before day 28 were already in‐
cluded in the 28‐day transition rates to death. Median survival times 
were reached at approximately five years (1819 days) for complete 
responders and at approximately four months (115 days) for nCR.
Kaplan‐Meier curves and fitted parametric models for sur‐
vival are depicted in Figure 2 for both response categories. AIC 
and BIC values are presented in Appendix S3. From a statistical 
point of view, the fit of the parametric models to the empirical 
data was similar. Nevertheless, the extrapolation after observa‐
tion was different. For instance, the extrapolation according to 
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the generalised gamma function predicted that 40% of the CR pa‐
tients survived more than 25 years after MSC treatment. This was 
not deemed plausible from a clinical perspective by the experts. 
Based on clinical expertise, the lognormal distribution would pres‐
ent the best balance between the statistical tests of fit and visual 
inspection for both CR and nCR.
3.3 | Results of the model simulation
At the 28‐day treatment evaluation, of the 100 simulated cases with 
aGvHD II‐IV, approximately 43 and 44 observations had a CR and 
nCR, respectively. The median survival time modelled for CR was 
3.2 and 0.5 years for nCR. Overall median survival for all patients 
irrespective of their response category was 9.6 months. Average 
per‐person life‐years were estimated at 0.32 years (ie, 3.8 months). 
In Figure 3, modelling results are plotted on the empirical Kaplan‐
Meier curves for CR and nCR. Table 2 depicts the estimated over‐
all survival probabilities for different years after the first response 
evaluation.
4  | DISCUSSION
In this study, we present a DM for the second‐line treatment of 
aGvHD. In line with current recommendations for good modelling 
practice, we involved an international group of clinical experts to de‐
velop this DM and used evidence available from the literature.3,5,23,25 
Consequently, we ensured that the model sufficiently represents 
current clinical practice.
The DM can serve manifold purposes. Updated with clinical evi‐
dence, it can be used by clinicians and researchers to estimate long‐
term health outcomes of different treatment alternatives. When 
costs are added to the clinical evidence, for example, from RETHRIM, 
economic evaluations can be performed to inform reimbursement 
decision‐makers on the implementation of treatment alternatives.
TA B L E  1   Transition rates from pre‐ to post‐MSC treatment
To
CR nCR Death
From aGvHD II‐IV 43.4% 43.7% 12.8%
CR: complete response; nCR: no complete response.
F I G U R E  2   Empirical Kaplan‐Meier curves with parametric model estimations [Colour figure can be viewed at wileyonlinelibrary.com]
F I G U R E  3   Modelling results; KM: 
Kaplan‐Meier; Markov trace = simulated, 
estimated survival of patients over 
time [Colour figure can be viewed at 
wileyonlinelibrary.com]
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To run a first model simulation, we searched for available evi‐
dence on both costs and clinical evidence on treatment alternatives 
for aGvHD. We found that MSCs for the treatment of SR‐aGvHD 
are widely studied. Therefore, we were able to integrate more than 
a decade of empirical data into our DM. Nevertheless, mainly due to 
the absence of randomised phase III studies, the number of patients 
included and the restricted follow‐up periods, we faced several chal‐
lenges in integrating the collected information. Consequently, we 
had made a number of assumptions.
First, MSC products and their administration varied between the 
studies. With the exception of the study by Fang et al33 where MSCs 
were derived from human adipose tissue, all other studies used bone 
marrow–derived products. In addition, the number of MSC infusions 
(between 1 and 21 infusions) as well as the dosage of infused MSCs 
(between 0.6 and 20 x106 cells per kg body weight) varied across the 
studies. In this regard, we assumed that type and administration of 
MSC products had no effect on transition probabilities or mortality 
rates. Whereas this made the integration of the study results possible, 
the data did not allow for further stratification to test potential MSC 
derivation–related or dose‐related effects on the response rates.
Second, there were not enough data available to estimate tran‐
sitions between response categories after a first response evalua‐
tion. We had assumed survival can be predicted based on the initial 
response category at 28 days post‐MSC transfusion. However, in 
clinical practice response categories may change in any direction 
after the first evaluation. Of the included studies, only Prasad et al36 
assessed response to MSCs in paediatric patients more than once. In 
this study, five of twelve patients further improved after day 32 to 
a complete remission. Future studies measuring response on several 
time points after MSC treatment could inform our model on subse‐
quent changes in response categories. Whereas this enables a better 
estimate for subgroups, the effect on the average survival of the en‐
tire population is most likely negligible.
Third, it needs to be noted that the simulation did not consider 
the underlying haematological disease, nor the patients’ age or sex. 
This choice was made as not all studies did report on these variables 
and any further stratification would have resulted in a reduction in 
the population on which the different estimates are based. However, 
we acknowledge that the underlying haematological disease and 
age and sex can be important determinants for long‐term survival. 
Detailed reporting on patient characteristics and their diagnosis may 
help to enable further analyses for these subgroups.
Our modelling results, however, did show the expected longer 
survival after MSC transfusion for patients that achieved CR at first 
response evaluation, when compared to patients with nCR. These 
estimates are in line with previous findings highlighting the impor‐
tance of complete response for long‐term survival.51‒56
To our knowledge, there are no long‐term survival results pub‐
lished for SR‐aGvHD patients treated with MSCs other than the 
two reports57,58 that are based on studies4,45 included in our study. 
Therefore, we attempted to compare our results to survival esti‐
mates of studies that tested other second‐line treatment options 
for aGvHD. To find suitable studies, we consulted the most recent 
NHS England clinical commissioning policy on the treatments for 
GvHD following HSCT.9 This guideline is based on an extensive and 
updated review of the literature and concludes that there is suffi‐
cient evidence only for extracorporeal photopheresis (ECP) to be 
routinely commissioned for the treatment of aGvHD. Therefore, we 
focussed on a comparison with ECP. For other treatment options 
such as infliximab, etanercept, inolimomab, alemtuzumab, pento‐
statin or MSCs, the reviewers found that there was no sufficient ev‐
idence available to propose the routine commissioning for aGvHD.
Regarding survival of aGvHD patients treated with ECP, the 
largest series was published by Greinix et al54 in a phase II prospec‐
tive study.9 Every week, 59 patients with steroid‐refractory or ste‐
roid‐dependent GvHD received two consecutive ECP treatments. 
CR and nCR was defined as in our study. The reported median 
survival was below 6 months after HSCT for patients with nCR, 
confirming our median survival estimations for nCR to MSC of 
approximately 6 months.54 In the study of Greinix et al54, median 
survival for complete responders was never reached during the 
reported follow‐up period of 9 years after HSCT. For this study, 
this implies that the probability of surviving nine years after HSCT 
would be approximately 59% for patients with a CR With an esti‐
mate of approximately 27% at ten years post‐MSCs, our estimates 
for patients with a CR are significantly lower. This may be ex‐
plained by differences in patient population before treatment (ie, 
Greinix et al54 included a higher number of patients with aGvHD 
grade II (61%)). In addition, the study by Greinix and colleagues 
was based on a limited amount of complete responders (n = 41).
Although we were able to demonstrate longer survival for patients 
with CR when compared to nCR, the relatively high mortality rate of 
SR‐aGvHD, even with MSCs, can still be regarded as unacceptably 
high. And although there were numerous studies reporting on MSCs 
as a treatment alternative for SR‐aGvHD, none of them included pa‐
tient‐reported outcomes (PROs) such as HRQoL. Updating our results 
with HOVON113 findings, including HRQoL measures, might improve 
the current survival estimates and show favourable treatment out‐
comes in terms of quality of life for MSCs when compared to placebo. 
However, until these study results are presented, this remains subject 
Response category
Years after the first response evaluation
1 2 5 10 20 50 80 99
CR 73.1 59.6 40.1 26.7 16.0 6.8 4.1 0
nCR 25.7 11.4 2.6 0.6 0.1 0 0 0
All 43.0 30.9 18.6 11.9 7.0 3.0 1.8 0
TA B L E  2   Estimated overall survival 
probability in per cent
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to speculation and the search for alternative (pre)treatments helping 
patients to achieve a complete response will have to continue.
5  | CONCLUSION
The designed DM provides a comprehensive overview on the sec‐
ond‐line treatment pathways for aGvHD in general. The model 
simulation with data from previously published studies on MSCs 
as a second‐line treatment option for aGvHD presented outcomes 
matching the literature as well as clinical expectations. This demon‐
strates the practicability and usefulness of the model. However, to 
date, only insufficiently detailed data are available to fully model all 
health states and to perform a cost‐effectiveness analysis. The yet 
restricted model simulation would therefore benefit from additional 
data, preferably from a phase III RCT. The integration of effective‐
ness results together with health‐related quality of life measures 
(eg, from the EQ‐5D questionnaires) and different cost components 
derived from the RETHRIM trial could overcome this limitation and 
enable a full cost‐utility analysis.
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